BTIG Positive on Progenics Pharma (PGNX) Following FDA Approval of RELISTOR as OIC Treatment (VRX)
Tweet Send to a Friend
BTIG affirms Progenics Pharmaceuticals (Nasdaq: PGNX) at Buy with a price target of $9 after Progenics and Valeant Pharma (NYSE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
